Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-08-16
    E.g., 2018-08-16

Articles

173065 items
12:00 AM, Jun 06, 1994  |  BC Week In Review | Company News  |  Deals

North American Bio deal

NBIO (Miami) created a German subsidiary through the acquisition of two German-based plasma collection facilities. NBIO, which has marketed its plasma-based products in Europe for more than 20 years, expects its European sales to provide...
12:00 AM, Jun 06, 1994  |  BC Week In Review | Clinical News  |  Regulatory

Cangene regulatory update

The Toronto company won a patent interference at the U.S. Patent and Trademark Office covering its Nucleic Acid Sequence-Based Amplification technology (NASBA). The interference, which began in May 1993, involved similar claims filed by Siska...
12:00 AM, Jun 06, 1994  |  BC Week In Review | Clinical News  |  Clinical Status

GS-504 nucleotide analog: Began Phase I/II trial

Gilead Sciences Inc. (GILD), Foster City, Calif.   Product: GS-504 nucleotide analog   Indication: Bone marrow transplant recipients at risk for cytomegalovirus (CMV) infection   Status: Began Phase I/II trial in 10 to 20 patients to assess...
12:00 AM, Jun 06, 1994  |  BC Week In Review | Clinical News  |  Clinical Status

Recombinant platelet factor-4: Began Phase I/II trial

Repligen Corp. (RGEN), Cambridge, Mass.   Product: Recombinant platelet factor-4 (rPF4)   Indication: Reverse heparin action after coronary artery bypass graft surgery   Status: Began Phase I/II dose-escalation trial in 20-25 patients, some of whom will be insulin-dependent...
12:00 AM, May 31, 1994  |  BC Week In Review | Company News  |  Deals

Celltech Biologics plc deal

Celltech (U.K.), a contract manufacturer of therapeutic monoclonal antibodies, entered into two agreements. The company will use its GS-System mammalian gene expression system to re-express a single chain protein under development by Bristol-Myers Squibb in...
12:00 AM, May 31, 1994  |  BC Week In Review | Clinical News  |  Clinical Status

Batimastat matrix metalloproteinase inhibitor: Began Phase II trial

British Bio-technology Group plc (BBIOY), U.K.   Product: Batimastat matrix metalloproteinase inhibitor, a blocker of the enzymes cancer cells use to digest connective tissue between cells to allow tumor growth   Indication: Malignant ascites in late-stage ovarian...
12:00 AM, May 31, 1994  |  BC Week In Review | Clinical News  |  Clinical Status

IDEC-CE9: IDPH and partner SmithKline Beecham began a Phase I/II trial

IDEC Pharmaceuticals Corp. (IDPH)   Product: IDEC-CE9.1, Primatized antibody directed at CD4   Indication: Rheumatoid arthritis   Status: IDPH and partner SmithKline Beecham began a Phase I/II trial in 45 patients with moderate to severe rheumatoid arthritis....
12:00 AM, May 31, 1994  |  BC Week In Review | Company News  |  Other News

NeoRx news

NERX (Seattle) said a class-action complaint has been filed in the U.S. District Court for the Western District of Washington at Seattle. According to the company, the suit alleges disclosure violations by NERX relating to...
12:00 AM, May 31, 1994  |  BC Week In Review | Company News  |  Other News

Energy BioSystems news

Construction has begun on a $1.5 million continuous operation pilot plant that will use the Houston company's enzyme-based biodesulfurization technology to remove sulfer from petroleum fuels. The pilot plant, scheduled for completion this year, will...
12:00 AM, May 31, 1994  |  BC Week In Review | Company News  |  Other News

Oncor other research news

The Cancer Research Institute at New York Medical College will conduct clinical studies to evaluate the utility of the Gaithersburg, Md., company's ApopTag apoptosis detection kit, which monitors the effectiveness of chemotherapeutic drugs. The studies...

Pages